NPTH Enpath Medical (MM)

Enpath Medical Reports First Human Use of Fastac(R) Flex Product Launch at Heart Rhythm Society Meeting Next Week MINNEAPOLIS, April 28 /PRNewswire-FirstCall/ -- Enpath Medical, Inc. (NASDAQ:NPTH) announced today that the first human use of its new FasTac(R) Flex epicardial lead implant tool occurred on Monday April 25, 2005. This unique deflectable implant tool was used to place two MyoPore(R) sutureless bipolar epicardial leads, also manufactured by Enpath, on the left ventricle of a patient in completing the left ventricular lead segment of her cardiac resynchronization therapy (CRT) system. CRT is used in the treatment of heart failure and is one of the fastest growing segments within Cardiac Rhythm Management devices. Jose Navia, M.D., a Cardiothoracic Surgeon at The Cleveland Clinic, performed the surgical lead implant. Dr. Navia played a role in the iterative development and trial process of the FasTac Flex. "This tool enabled me to reach the epicardial surface at the proper angle to easily place both leads into the myocardium," Dr. Navia said. "Enhancing precision and improving care is the goal." Dr. Navia is collaborating with multiple medical disciplines to treat heart failure at The Cleveland Clinic's Center for Electrical Therapies for Heart Failure. The FasTac Flex has been cleared for use in the U.S. The official product launch will take place at the Heart Rhythm Society meeting May 4-7 in New Orleans. About Enpath Medical Enpath Medical, Inc., headquartered in Plymouth, Minnesota, is a leader in the design, development, manufacture and marketing of percutaneous delivery systems and stimulation leads technologies. Its products include venous vessel introducers, epicardial and endocardial stimulation leads, safety needles and other products for use in pacemaker, defibrillator, catheter and infusion port procedures as well as neuromodulation and hearing restoration markets. Its products are sold worldwide through partnering relationships with other medical device companies. DATASOURCE: Enpath Medical, Inc. CONTACT: Investors, Doug Sherk, +1-415-896-6820, or Jennifer Beugelmans +1-415-896-6820, or Media, Chris Toth, +1-415-896-6820, all of the EVC Group Web site: http://www.enpathmed.com/

Copyright